Fauci: GSK/NIAID Ebola vaccine safety 'looks good'
This article was originally published in Scrip
Executive Summary
Safety results appear positive from a Phase I trial of an experimental Ebola vaccine being jointly developed by GlaxoSmithKline and the National Institute of Allergy and Infectious Diseases (NIAID), according to the head of that US government agency.